INTRODUCTION
Variations in the genes encoding drug metabolizing enzymes have long been recognized as important determinants of drug disposition and response. Indeed, certain single nucleotide polymorphisms (SNPs) in cytochrome P450 (CYP) enzymes such as CYP2C9, CYP2C19, and CYP2D6 are well known determinants of altered drug responsiveness, and often associated with drug toxicity or in some cases, loss of therapeutic efficacy (1, 2) . More recently, there has been an increasing appreciation of the role of drug transporters in drug disposition. For example, the product of the MDR1 gene, P-glycoprotein (P-gp), is an efflux transporter involved in the oral drug absorption, distribution to certain tissues, and biliary and urinary excretion of many drugs.
Moreover, P-gp has been shown to have broad and overlapping substrate specificities to CYP enzymes (3) . Furthermore, polymorphisms in the MDR1 gene have been associated with alterations in digoxin (4) and fexofenadine (5) disposition.
Removal of drugs/solutes from the portal circulation involves uptake into hepatocytes as the obligatory first step. While passive diffusion can be involved in the uptake of many uncharged or lipophilic compounds, carrier-mediated processes are often critical for the efficient hepatic uptake of solutes and many drugs. Among the transporters expressed at the basolateral membrane of hepatocytes, members of the 4 been established as the major OATPs located at the basolateral membrane of human hepatocytes.
OATP-C (gene symbol SLC21A6), also known as liver specific transporter-1 (LST-1)(10) or OATP2 (11, 12) is involved in the hepatic uptake of a broad array of endogenous compounds such as taurocholate (11) , estrone sulfate (8) , estradiol 17ß-Dglucuronide (10), leukotriene C 4 (10) , prostaglandin E 2 and thyroid hormone (10) .
Recently, OATP-C has also been shown to mediate the cellular uptake of bilirubin and its glucuronide conjugates (12, 14) . Furthermore, a variety of drugs and xenobiotics including the organic anion bromosulfophthalein (9, 14) , the glycoside oubain (9) , the peptidomimetic BQ-123 (9) and the HMG-CoA-reductase inhibitor pravastatin (11) have been identified as OATP-C substrates. Accordingly, given the extent of its substrate specificity for endogenous and exogenous compounds, it is conceivable that genetic polymorphisms in OATP-C may have significant pharmacologic, toxicologic and pathologic consequences.
In this report we describe the identification of single nucleotide polymorphisms (SNPs) in OATP-C and their prevalence in European-American and African-American populations. We show that a number of frequently occurring variant alleles are associated with profound reduction in transport activity. 6 in a final reaction volume of 50 µl. The complete oligonucleotide primer sequences are provided in Table 1 . After the PCR reaction, non-isotopic SSCP analysis was used to identify the presence of OATP-C allelic variants (16) . The gel run-time was varied to yield optimal separation of the single-strands; for the most part, run-times of 4 -6 hr were sufficient. Variations in the single-strand mobility patterns were clearly visualized.
Full-length cDNA cloning
Human liver samples (Nashville Regional Organ Procurement Agency, Nashville, TN) from Caucasian donors without any history of underlying liver pathology or prior medications were utilized in the total RNA extraction, using Trizol ® reagent (Gibco BRL). Direct cloning of OATP-C full-length cDNA was obtained by RT-PCR using the primer pair 5´-GATATCTATATTTCAACCATGGACC-3´ and 5´-TTAACAATGTGTTTCACTATCTGCCCCAG-3´. Four independent OATP-C clones from each liver were fully sequenced. SNPs were deemed to be authentic and present if the polymorphism was observed in at least two independent clones.
Site-directed mutagenesis:
A number of full-length cDNA clones derived from human liver samples contained various OATP-C mutations, making them suitable for in vitro expression studies. However, site-directed mutagenesis was utilized to create additional variant sites known to be present among European-and African-American subjects. Point mutations were introduced into the wildtype (OATP-C*1a) using the QuikChange™ sitedirected mutagenesis kit (Stratagene, La Jolla, CA). Oligonucleotides containing the Val174Ala, Asn432Asp and Asp655Gly were used to create OATP-C*5, OATP-C*7, and 7 OATP-C*9 expression vectors, respectively. Two mutant sites, Arg152Lys and Asp241Asn, had to be introduced sequentially in order create the OATP-C*1c expression vector. Presence of the mutations was verified by full sequencing.
Haplotype Assignment: Haplotypes could be defined when subjects homozygous at a single polymorphic site or multiple sites were identified. Additionally, when subjects homozygous for a SNP at one site, were found to be heterozygous for another SNP at a different site, an allelic assignment was possible. Furthermore, presence of SNPs in the liver-derived full-length cDNAs provided unequivocal verification of haplotype.
Determination of Genotypic Frequencies:
PCR-restriction fragment length polymorphism (PCR-RFLP) analysis was used to determine the genotypic frequencies of 9 non-conservative polymorphisms. The primers (based on GenBank accession number AC022335) and restriction endonucleases used for PCR-RFLP analysis are summarized in Table 1 . Allele-specific PCR (AS-PCR) was performed to obtain genotypic frequencies for 3 polymorphisms (see Table 1 for primers).
Expression of Variant OATP-C Alleles: HeLa cells grown in 12-well plates
(approximately 0.8 x 10 6 cells/well) were infected with vaccinia at a multiplicity of infection of 10 pfu/cell in serum-free OPTIMEM I medium (Gibco BRL) and allowed to adsorb for 30 min at 37ºC. Cells in each well were then transfected with 1µg of wildtype or variant OATP-C cDNA packaged into pEFHis6-Topo vector (Invitrogen), along with Lipofectin TM (Gibco BRL) and incubated at 37ºC for 16 hr. The parental plasmid lacking 8 any insert was used as control. Transport was then evaluated using labeled drug substrates as outlined previously (17) . In order to measure the estrone sulfate and estradiol 17ß-D-glucuronide transport kinetics, radiolabeled drug uptake during the linear phase (first 3 min), was assessed in the presence of varying concentrations of unlabeled compound. Passive diffusion was determined by carrying out parallel experiments using the parental plasmid DNA lacking the transporter cDNA, and this value w as then subtracted from the total uptake rate seen in the presence of the transporter cDNA.
Michaelis-Menten type non-linear curve-fitting was carried out to obtain estimates of the maximal uptake rate, V max , and the concentration at which half the maximal uptake occurs, K m (Prism TM , GraphPad, San Diego, CA). All experiments were carried out in duplicate on at least two to three separate experimental days. 
RESULTS

Polymorphisms in OATP-
OATP-C Genotypic Frequencies:
With a combination of PCR-RFLP ( Fig. 2B ) and AS-PCR, the genotypic frequencies of OATP-C SNPs were determined (Table 1) . Several variants were found at a relatively high incidence (A388G>C463A>T521C>A2000G>G1463C) and their genotypic frequencies appeared to be dependent on race (Table 1) . G388C and G1463C polymorphisms were more common in African-than European-Americans; however the converse was true for C463A and T521C mutations (p<0.05). The most common polymorphisms in AfricanAmericans were A388G (74%), A2000G (34%) and G1463C (9%) whereas the A388G (30%), C463A (16%) and T521C (14%) were predominant among European-Americans.
Other non-synonymous polymorphisms were observed at low genotypic frequencies (<2%) in this study population and their racial dependency could not be established.
With regards to the synonymous polymorphisms, G411A occurred at a higher frequency in African-than European-Americans (41% vs. 18%, p<0.05) while C571T was more common in European-Americans (54% vs. 5%, p<0.05).
Functional Analysis of OATP-C Haplotypes:
An array of expression plasmids comprising 16 OATP-C allelic variants (Fig. 1B ) was constructed. When expressed using the recombinant vaccinia system (VTF-7), OATP-C*1a was capable of transporting known substrates including BQ-123, estrone sulfate, taurocholate and estradiol 17ß-Dglucuronide ( Fig. 3A) . Moreover, we found that methotrexate is a novel substrate for OATP-C (Fig. 3A) . To determine the relative transport efficiencies of the OATP-C variants, we focused on estrone sulfate and estradiol 17ß-D-glucuronide as they appeared to be the most efficiently transported substrates among the compounds tested. Under linear kinetic conditions, estrone sulfate transport activities of the originally reported OATP-Cs (*1a, *1b and *1c), were not different from each other (Fig. 3B ). For estradiol 17ß-D-glucuronide, transport activities with OATP-C*1a and *1b were comparable and slightly greater than *1c (Fig. 3C) . With a number of other OATP-C variants (*2, *3, *5, *6, *9, *10, *12 and *13), estrone sulfate transport activities were significantly lower than the reference allele (*1a) (Fig. 3B) . Similar results were seen for estradiol 17ß-Dglucuronide transport except that OATP-C*7 now had slightly lower transport activity and *10 was indistinguishable from the reference allele (Fig. 3C ). For the majority of variants, the transport activity differences were not associated with alterations in total OATP-C protein expression since immunoblot analysis ( For a more comprehensive characterization, the concentration-dependent uptake kinetics of estrone sulfate was examined for all 16 allelic variants and the results are summarized in Table 2 . Some variants (e.g. OATPC*5, substrates than estrone sulfate, concentration-dependent uptake kinetics were also determined using estradiol 17ß-D-glucuronide. In general, similar trends were observed for the kinetics of estradiol 17ß-D-glucuronide among OATP-C variants when compared with estrone sulfate (Fig. 4A and 4B ). Intrinsic clearances for estradiol 17ß-Dglucuronide were lower for OATP-C*2, *3, *5, *6 and *9 variants when compared to *1a
( Fig. 4B) , and for the most part, this was due to decreased V max . Upon association of the transport activities with the corresponding SNPs, we were able to deduce that that
(OATP-C*9) and Asp655Gly ( OATP-C*10) mutations significantly reduced estrone sulfate and/or estradiol-17ß-D-glucuronide transport activities of OATP-C. Intrinsic clearance values for allelic variants containing any one of these amino acid substitutions were markedly lower than OATP-C*1a and ranged from 7% to 53% of the reference allele (Table 2 and Fig. 4 ). For the OATP-C*3 allele, it was not possible to establish whether Val82Ala and/or Glu156Gly mutations were important for the reduced OATP-C activity.
Cell Surface Expression of OATP-C Variants:
With the exception of OATP-C*2, reduced transport activity for OATP-C variants did not appear to be associated with alterations in the expression of the total cellular level of this transporter (Fig. 3D) .
However, differences in cell surface expression could account for the decreased transport capacity of variant OATP-C transporters. Accordingly, cell surface biotinylation experiments were performed to specifically capture plasma membrane associated OATP-C. The results for such experiments revealed that the plasma membrane expression of OATP-C*2, *3, *5, *6 and *9 were markedly reduced in comparison to *1a.
Densitometric analysis indicated that the fractional (% total) surface expression of OATP-C*2, *3, *5, *6 and *9 ranged from 10% to 35% of that observed for *1a.
Interestingly, the cell surface expressed OATP-C's were of a larger apparent molecular weight than the major 71 kDa band observed in total cell lysates (Fig. 5 ). This larger form was similar in size to the major ~84 kDa band observed from human liver. The enrichment of cell surface proteins within these biotinylated fractions was evidenced by the lack of immunodetectable calnexin (an intracellular protein) in the samples (Fig. 5) .
Overall Interestingly, the G1463C (Gly488Ala) polymorphism, predicted to be located on extracellular loop 5, was associated with a significant reduction in intrinsic clearance, relative to the wildtype allele (Table 2) . Interestingly, the Gly488Ala (OATP-C*9)
amino acid substitution takes place in an area of the protein which could be considered a signature motif for all members of the OATP transporter family (Fig. 6 ). Thus the presence of such a conserved domain in a putative extracellular loop, along with the observation that this and additional 2 SNPs identified in this region (N432D, D462G)
were associated with either a reduced V max ,increase in K m , or alteration in both values strongly suggests an important role of this region to substrate-transporter interaction. This is in distinct contrast to the 4 SNPs in extracellular loop 2 (N130D, R152K, P155T, E156G), associated with minimal or modest changes in the observed transport activity.
In terms of expressed level of variant OATP-Cs, other than OATP-C*2, we did not observe any readily discernable differences in the total expressed level of the transporters. However, when cell surface biotinylation experiments carried out, several OATP-C variants (*2, *3, *5, *6, * 9) were found to have decreased fractional cell membrane expression as compared to the wildtype allele (Fig. 5) , thus explaining, in part, the observed alterations in transport activity. For example, only the V max values were significantly reduced for OATPC*5-mediated transport of estrone-sulfate and estradiol 17ß-D-glucuronide (Fig. 4) , suggesting that the V174A substitution predominantly altered cell surface expression, but not transport activity. For the most part however, marked differences in the observed K m and V max values were evident, even among OATP-C variants with similarly reduced cell surface expression, suggesting that the encoded mutations also alter the affinity and efficiency of this transporter. It will be necessary to further explore how amino acid variations in OATP-C affect transporter trafficking and turnover and whether such in vitro findings also apply to hepatocytes in vivo.
The incidence of functionally deleterious mutations in our study population was for the most part, relatively low. However, high allelic frequency was observed for the T521C (V174A) transition in European-Americans (14%) and the G1463C transversion Since the extent of hepatic uptake determines the intracellular drug concentration, polymorphisms in an uptake transporter such as OATP-C may be particularly important when hepatic drug clearance is rate-limited by uptake, such as in the case for the hydrophilic OATP-C substrate pravastatin (11, 19) . It is expected that as more drugs are identified as OATP-C substrates, the consequence of genetic heterogeneity in OATP-C to in vivo drug disposition will become more evident. In addition, the contribution of OATP-C in comparison to other OATPs in the overall hepatic uptake of drugs must also be considered. Accordingly, t he substrate specificities for all hepatic OATPs and their attendant polymorphisms will need to be defined. Moreover, regulatory control mechanisms involved in the transcriptional activation of OATP-C will need to be defined and must be taken into account to more fully appreciate the implications of OATP-C polymorphisms.
In a recent report, Cui and collaborators (14) and cell surface proteins (25 µl, 50% of biotinylated proteins captured on streptavidin beads) (right panels) were subjected to SDS-PAGE and transferred onto nitrocellulose.
Blots were probed with anti-OATP-C antibody (top panels) then stripped and probed with anti-calnexin antibody (bottom panels). Immunoblots for total and cell surface proteins were exposed to X-ray film for identical periods of time. GFIDGSFEIGNLLVIVFVSYFGS  GLIDGGFEIGNLLVIVFVSYFGS  GLIDGGFEIGNLLVIVFVSYFGS  GFINGSFEIGNLLLIIFVSYFGT  GLLASFNEVGNTALIVFVSYFGS  GVIASSFEIGNLALILFVSYFGA  GLIASSYDIAACLCLTFVSYFGG  GVIDGSFEIGNLLVITFVSYFGA  GLINGSFEIGNLFFIVFVSYFGT  GLINGSFEIGNLLLIIFVSYFGT  GFINGSFEIGNFLLIIFVSYFGT  GLINGSFEVGNLLLIIFVSYFGR  GFIDGSFEIGNLLVIVFVSYFGS   MWIYVFMGNM  MWIYVLMGNM  TWIYVLMGNM  MWVYVLVGNI  VVGIMFVAQT  MYLLLIGAQV  YQLVFMLGQF  MWIYVFLGNL  MWICVMVGNI  MWIYVLVGNI  MWIYVLVGNI  MWIYVLVGNI  MWIYVFMGNM   VSSYIGAFT  VSGFIGSFT  ISSFIGSFT  FNAFVNMIS  SSMAAGMAT  IAVVAGFAA  ATLITGMST  FNSLFGMVT  VNGFINKFT  FNAFINSFT  INAFINMFT  VNGFVSIFT  VSSYIGAFT   PCLAGCKSSS  PCLAGCKSFR  PCLAGCKSFR  ACLAGCETSI  PCHAGCSSWV  ACFAGCNSTN  LCHAGCPAAT  ACLAGCQTSN  ACLAGCKKFV  ACLAGCEKSV  ACLAGCKKSV GFIDGSFEIGNLLVIVFVSYFGS  GLIDGGFEIGNLLVIVFVSYFGS  GLIDGGFEIGNLLVIVFVSYFGS  GFINGSFEIGNLLLIIFVSYFGT  GLLASFNEVGNTALIVFVSYFGS  GVIASSFEIGNLALILFVSYFGA  GLIASSYDIAACLCLTFVSYFGG  GVIDGSFEIGNLLVITFVSYFGA  GLINGSFEIGNLFFIVFVSYFGT  GLINGSFEIGNLLLIIFVSYFGT  GFINGSFEIGNFLLIIFVSYFGT  GLINGSFEVGNLLLIIFVSYFGR  GFIDGSFEIGNLLVIVFVSYFGS   MWIYVFMGNM  MWIYVLMGNM  TWIYVLMGNM  MWVYVLVGNI  VVGIMFVAQT  MYLLLIGAQV  YQLVFMLGQF  MWIYVFLGNL  MWICVMVGNI  MWIYVLVGNI  MWIYVLVGNI  MWIYVLVGNI  MWIYVFMGNM   VSSYIGAFT  VSGFIGSFT  ISSFIGSFT  FNAFVNMIS  SSMAAGMAT  IAVVAGFAA  ATLITGMST  FNSLFGMVT  VNGFINKFT  FNAFINSFT  INAFINMFT  VNGFVSIFT  VSSYIGAFT   PCLAGCKSSS  PCLAGCKSFR  PCLAGCKSFR  ACLAGCETSI  PCHAGCSSWV  ACFAGCNSTN  LCHAGCPAAT  ACLAGCQTSN  ACLAGCKKFV  ACLAGCEKSV  ACLAGCKKSV 
